The relationship between blood pressure variability and outcome in acute ischemic stroke

Kamil Kowalczyk, Dariusz Gąsecki

Department of Adult Neurology, Medical University of Gdańsk, Poland

Abstract

Stroke is the second most common cause of mortality. Ischemic stroke is approximately 10 times more common than haemorrhagic stroke. The strongest risk factor for ischemic stroke is hypertension, thus reduction of blood pressure decreases the risk of ischemic stroke. However, the prognostic importance of blood pressure after is unclear. The problem is even more complex considering blood pressure variability (BPV), i.e. continuous changes of blood pressure values. The aim of this review is to discuss the very short-term, short-term, mid-term, and long-term blood pressure variability in the context of clinical outcome in patients after acute ischemic stroke. Most of the studies have shown that increased BPV in ischemic stroke patients is associated with poorer prognosis, however in some of them there was not association between BPV and outcome.

Keywords: outcome · ischemic stroke · blood pressure variability

Citation


Introduction

Worldwide, stroke is the second most common cause of death, after ischemic heart disease, and the second most common cause of reduced disability-adjusted life-years [1-3]. In Poland in 2009-2013, an annual hospital admission rate of ischemic stroke patients (standardized by age) is 127/100,000 for females and 193/100,000 for males [4]. Hypertension is the strongest risk factor for ischemic stroke. In the INTERSTRO-
AIS remains challenging. Recommendations included in the current guidelines on BP treatment in AIS patients are not evidence-based [10, 15]. Present data suggest that lowering very high blood pressure in the early phase of AIS may be beneficial, but they need further confirmation. Data on raising blood pressure in the case of hypotension associated with focal cerebral ischemia are also inconsistent. Thus, due to insufficient data there is a continued concern about management of BP in patients with AIS [14]. Moreover, high blood pressure should be lowered for the purpose of secondary prevention after the acute phase of ischemic stroke or transient ischemic attack [10, 15].

Despite all the controversies, the role of BP and its management in acute stroke seems to be meaningful [13, 16-18]. However, not only casual BP measurements affect the prognosis after AIS, but also BP profiles may be an important factor. Evidence concerning their role in ischemic stroke is scarce.

There is a paucity of the available data on the course of BP in ischemic stroke. In the vast majority of patients, during the acute phase of ischemic stroke blood pressure usually rises during the first hours and then declines over the time (a phenomenon known as acute hypertensive response, occurring in over 60% of such patients) [19-20]. Blood pressure upon admission is higher in patients with a history of hypertension [21]. Moreover, decrease in BP during the first 4 hours after admission is seen in patients with mild stroke and with subsequent favourable outcome [21]. On the contrary, no decline in BP is observed in patients with severe stroke and unfavourable outcome [21].

The variation in blood pressure over time is known as blood pressure variability (BPV) [22]. The role of BPV in ischemic stroke is poorly understood. BPV was found to be higher in ischemic stroke patients receiving antihypertensives (without specifying the drug class) just before administration of thrombolytics [23]. More precisely, calcium-channel blockers decrease BPV and reduce the risk of stroke [24]. Longitudinal observations of the general population in Japan showed that increased BPV was associated with higher stroke mortality [25]. The aim of this review is to discuss the role of BPV in prognosis after ischemic stroke. Other interesting factors that may influence ischemic stroke outcome are changes of blood pressure during the sleep/wake cycle, however the topic is beyond the scope of this review and requires further study.

### Indices of blood pressure variability

Blood pressure changes substantially between beats (very short-term BPV); minutes, hours or from day to night (within 24 hours, short-term BPV); between different days (mid-term BPV) or between clinic visits (long-term BPV) [26-27]. Indices used for assessment of BPV are as follows: standard deviation (SD), coefficient of variation (CV, defined as average SD divided by the mean BP and multiplied by 100), variation independent of mean (VIM, a transformation of SD which is not correlated with mean), average real variability (ARV, defined as the average of the absolute differences between successive BP measurements), successive variation (SV, defined as the square root of the average squared difference between consecutive BP measurements) [26, 28-30]. Novel approach includes more advanced methods, such as spectral analysis of the different frequency components [26, 31].

### Pathomechanism of blood pressure variability

There are several mechanisms having an impact on BPV; e.g., very short- and short-term BPV is caused by humoral, rheological, behavioural, and emotional factors; impact of reflex and central autonomic modulation or arterial elasticity; mid- and long-term BPV, by behavioural factors, arterial stiffness, as well as seasonal climatic change, or poor control of blood pressure in treated patients [26]. Detailed description of the BPV pathomechanism is beyond the scope of this review and may be found elsewhere [32-33].
Very short-term blood pressure variability

Dawson et al assessed beat-to-beat BPV in 92 acute stroke patients [34]. The subjects had Finapres non-invasive BP monitor fitted within 24 to 72 hours after symptom onset. SD of beat-to-beat recordings (SBP, DBP, pulse pressure and mean arterial pressure) was calculated. The patients were classified as dead/dependent or independent (mRS ≤ 2 points) on the basis of assessment at 30 days after stroke. Patients with higher DBP and mean arterial pressure variability were of greater risk of poor outcome.

Short-term blood pressure variability

In a Spanish study, Delgado-Mederos et al assessed the impact of BPV on enlargement of diffusion-weighted imaging (DWI) ischemic lesion and clinical outcome [35]. 80 stroke patients with occlusion of middle cerebral artery, treated with intravenous tissue plasminogen activator (tPA) were included into the study. All of them had DWI before and 36-48 hours after thrombolysis. Repeated SBP and DBP measurement were recorded for 24 hours since admission. BP variability was defined as SD of all BP measurements. In non-recanalized patients, SBP and DBP variability was higher than in recanalized patients. In the whole study population, higher SBP and DBP variability were associated with greater lesion growth on DWI. Interestingly, the correlation between BPV and DWI lesion expansion was higher in patients with persisting occlusion of the medial cerebral artery. In these cases, the correlation of SBP variability (but not of DBP variability) and lesion growth was still present after adjustment for baseline stroke severity, vascular risk factors, localisation of occlusion and the use of antihypertensives. Contrary to this, in patients who recanalized, DWI infarct size was not affected by BPV. Early clinical improvement (defined as a decrease of ≥ 4 points on the National Institutes of Health stroke scale [NIHSS] score at 24 hours after stroke onset) was correlated with lower BP variability. Moreover, higher SBP variability was associated with higher incidence of poor 3-month outcome defined as a modified Rankin scale (mRS) score ≥ 3. The associations of BPV and clinical outcome (early clinical improvement and frequency of 3-month poor outcome) were more evident in the non-recanalized study subjects.

Liu et al studied the impact of systolic BPV on severe haemorrhagic transformation after intravenous thrombolysis [36]. They included 461 patients and measured the following BPV parameters: SD, SV, average squared difference between rise and drop successive measurements (SVrise and SVdrop), and maximum of SV rise and SV drop (SVrisemax and SVdropmax) after quartering 0- to 24 h BP course. Severe haemorrhagic transformation (sHT) was defined as parenchymal haematoma or symptomatic intracerebral haemorrhage (haemorrhagic transformation and an increase of 4 or more points in NIHSS score). Unfavourable outcome was defined as 2-6 points in mRS at day 90. They found that SBP-SD and SBP-SV within 24 hours were positively associated with sHT. Within the first 6 hours, only SBP-SV, SBP-SVrise, and SBP-SVrisemax were associated with sHT. Higher SBP-SV, SBP-SVrise, SBP-SVdrop, SBP-SVrisemax, and SBP-SVdropmax among all studies periods (0-24h, 0-6 h, 6-12 h, 12-18 h, 18-24 h) were significantly associated with unfavourable outcomes at day 90 with the exception of SBP-SV drop 0-6 (no relationship).

Endo et al assessed the clinical outcome in stroke patients receiving intravenous thrombolysis (0.6 mg/kg dose of rt-PA, recombinant tissue plasminogen activator) and early BPV [23]. In the study, 527 patients were enrolled. BP was measured before administration of rt-PA and every 4 hours after completing the administration (in total, 8 measurements). Then SD, CV, and SV as the square root of the average difference in BP between each of the 8 successive measurements were calculated. Outcomes were as follows: intracerebral haemorrhage within the first 36 hours, modified Rankin Scale (mRS) score of 0 to 1, and death at 3 months. Higher systolic BPV (SD, CV, SV) was associated with symptomatic intracerebral haemorrhage and death.

In study by Manning et al, a post-hoc analysis of data from two randomized controlled trials (CHHIPS and COSSACS) was undertaken [37]. In COSSACS study, participants with stroke symptom onset < 48 hours were recruited, while in CHHIPS study, patients with symptom onset < 36 hours were enrolled. In both studies, baseline (prior to randomization) BP was measured (2 sets of 3 BP measurements, 10 minutes apart). The following BPV measures were obtained: SD, CV, ARV, and VIM for SBP and DBP. In both studies, the primary outcome was death or major disability (mRS > 3 at 2 weeks). Regarding COSSACS study, 706 patients were analysed. To assess the relationship between BPV and outcome, adjusted logistic regression was carried out. In the analysis, there was no statistically significant relationship between BPV and death and disability at 2 weeks. In terms of CHHIPS study, no association between short-term BPV and clinical outcome was found.

Tomii et al evaluated impact of changes of BP on stroke outcome after intravenous (i.v.) thrombolysis [38]. 125 stroke patients who received intravenous rt-PA within 3 hours of symptoms onset were enrolled.
During the first 24 hours, BP parameters were measured (immediately after hospital admission as well as after starting rt-PA infusion: every 15 minutes during the first 2 hours, every 30 minutes from 2 to 6 hours, and every 1 hour from 6 to 24 hours). Then CV was obtained. The primary outcome was mRS < 3 points at 3 months, and the secondary outcome were as follows: early neurological improvement (a reduction of at least 4 points from the baseline NIHSS score or a total NIHSS score of 0 or 1 at 24 hours after i.v. tPA) and intracerebral haemorrhage (found on CT within 36 hours after i.v. rt-PA). In the analysis, CV of SBP and pulse pressure were positively correlated with intracerebral haemorrhage.

In another Japanese study, Tomii et al. investigated the effect 24-hour blood pressure on recovery from AIS. They enrolled 104 ischemic stroke patients admitted to hospital within 24 hours of symptom onset [39]. 24-hour ambulatory BP monitoring was started at 10:00 on the 2nd and 8th days of hospitalization. Subsequently, CV for SBP, DBP, and MBP was determined. The outcomes were independent activities of daily living (mRS ≤ 2 points) and poor outcome (mRS ≥ 5 points) at 3 months. In multivariate analysis, CV of pulse pressure on the second day was inversely associated with independent activities daily living.

Yong et al. investigated the relationship between BPV and functional outcome, mortality and haemorrhagic complications in 793 patients after acute ischemic stroke included in the ECASS-II study [40]. SV was used to represent BPV. 7-day haemorrhagic transformation and 90-day favourable outcome (mRS score of 0 or 1 point) as well as all-cause mortality were the end points. The results suggest that higher SBP-SV was related to the greater risk of parenchymal haemorrhage (PH) in rtPA-treated group and inversely associated with 90-day favourable outcome in the entire study population. On the other hand, in the placebo-treated participants, there was an inverse association between high SBP-SV and 90-day favourable outcome.

Kellert et al observed 427 patients with acute stroke and investigated the effect of BPV on the development of intracerebral haemorrhage (ICH) after intravenous thrombolysis [41]. BPV was defined as SV and maximum SV for SBP and DBP. Patients were divided into high (> median) and low (≤ median) systolic and diastolic BPV. ICH was diagnosed on the basis of neuroimaging studies; symptomatic ICH (sICH) was defined as detection of blood and NIHSS worsening by 4 or more points or leading to death. They found that there were no differences between non-IICH, ICH and sIICH groups regarding BPV, however patients with high (> median) SBP-SD had increased risk of occurrence of sIICH (p = 0.03). Moreover, lower SBP-SD was associated with independent functioning (mRS score ≤ 2) at day 90 (p < 0.001), and mortality at day 90 was more frequent in the high (> median) diastolic SBP-SD group (p = 0.04). The multivariate analysis for the 3-month outcome showed that high systolic BPV was associated with poor outcome.

In a more recent retrospective study of 215 patients de Havenon showed that increased SD, CV, and SV for SBP as well as increased SD and CV for DBP measured within 0-24 hours after admission due to AIS were associated with higher mRS assessed between 30 and 365 days [42]. Only patients with anterior circulation stroke were included in the study. The outcome was worse in the case of proximal artery occlusion and lower mean blood pressure.

In 2004, Castillo et al published their paper on the relationship between SBP, DBP, drop in BP and stroke outcome [43]. Their study included 304 patients with AIS admitted in < 24 hours after symptom onset. In all patients, BP on admission and on the first day was assessed. Reduction in SBP and DBP > 20 mm Hg between the first-day and admission measurements resulted in higher frequency of early neurological deterioration defined as a decrease in the Canadian Stroke Scale (CSS) score ≥ 1 point within the first 48 hours after admission, increased infarct volume and worse outcome (CSS ≤ 7 points at 3 months).

In a retrospective study of 2545 ischemic stroke patients by Kang et al, the association of SBP-SD calculated on days 1, 2, and 3 and early neurological deterioration (END, increase of ≥ 2 points in NIHSS score) at days 1, 2, and 3 was checked [44]. It was shown that higher SBP-SD at day 2 was associated with END at day 2, and SBP-SD at day 3 was associated with END at day 3.

Buratti et al. evaluated 89 ischemic stroke patients with internal carotid artery occlusion [45]. They found that higher values of SD and CV for both SBP and DBP calculated within 48 hours after disease onset were significantly associated with poor outcome assessed at 3 months using the mRS score.

Sare et al. investigated the relationship between blood pressure variability and outcome in ischemic stroke patients admitted to hospital within 8 hours from symptoms onset who received placebo treatment instead of rt-PA [13]. Systolic and diastolic BPV was calculated as CV over 24 and 72 hours. At day 7, neurological impairment (NIHSS > 7); and at day 90, functional outcome (good, mRS ≤ 2; and poor, mRS > 2) were obtained. It was shown that (after adjustment for age, sex, time to inclusion, baseline NIHSS, hypertension in history, antihypertensive treatment within the first 7 days) increased systolic BPV was associated with poor 90-day functional outcome but not with early neurological impairment.
Mid-term blood pressure variability

Chung et al evaluated the relationship between BPV and early neurological deterioration (END). In the study, patients with acute ischemic stroke hospitalized within 24 hours after symptoms onset were enrolled [46]. Finally, in the study period (over 3 years), 1161 patients were analyzed. Blood pressure was measured for 72 hours of hospitalization. The following blood pressure variability parameters were calculated: standard deviation (SD) and coefficient of variation (CV) for SBP and DBP. END was defined as an increase of at least 2 points in the NIHSS score or increase of at least 1 point in the level of consciousness or motor items of the NIHSS, or the occurrence of new neurological deficits within the first 72 hours after admission to hospital. The study showed that all BPV parameters were higher in patients with END than in patients without END. Furthermore, SBP SD, SBP CV, DBP SD, and DBP CV were linearly associated with END, even after adjustment for mean BP and potential clinical variables (among others, age, sex, history of stroke or transient ischemic attack, diabetes mellitus, atrial fibrillation, Trail of Org 10172 in Acute Stroke Treatment [TOAST] classification, and baseline NIHSS score).

Ko et al assessed relationship between BPV and haemorrhagic transformation (HT) in ischemic stroke patients [47]. The authors enrolled 792 patients hospitalized within 24 hours after stroke onset whose initial gradient echo MRI showed no haemorrhagic transformation. BP was measured during the first 72 hours and the following BPV parameters were obtained: SD and average squared difference between successive measurements (SV) for SBP and DBP. Presence of HT and microbleeds was evaluated on all brain images carried out within first 2 weeks after stroke. The analysis showed that higher DBP SD and DBP-SV were associated with HT. The relationship remained significant for DBP-SD after adjustment for mean SBP, age, time from onset to admission to hospital, initial stroke severity, diabetes mellitus, stroke subtype, thrombolysis, initial glucose, and total cholesterol.

In the TAIST trial, the relationship between BPV defined as SD of SBP and early outcome (at day 10) was assessed [48-49]. In the study, 1479 patients with acute ischemic stroke were randomized. Death or neurologic deterioration (decrease of ≥ 5 points in the Scandinavian Stroke Scale [SSS] or decrease of > 2 points in consciousness part of the SSS) and neurologic deterioration alone were associated with increased SBP variability in univariate analysis and after adjustment for baseline prognostic factors, time to treatment and treatment assignment (high-dose tinzaparin, medium-dose tinzaparin, and aspirin). Recurrent stroke (ischemic, haemorrhagic, or unknown type) was associated with higher SD of SBP in univariate logistic regression, but the relationship lost its statistical significance after adjustment for the aforementioned factors.

In another study by Kang et al, the effect of BPV in the subacute phase of ischemic stroke on the 3-month functional outcome was assessed [50]. 2271 participants hospitalized within 48 hours of symptoms onset were enrolled into this retrospective observational study. The subacute stage was defined as the time period after 72 hours from ischemic stroke symptom onset to discharge or transfer to rehabilitation unit. SD and CV of systolic and diastolic blood pressure were obtained. Clinical outcome was assessed at 3 months using mRS. Poor outcome was defined as a 3-month mRS score of 2 to 6 if the baseline NIHSS score was ≤ 7 points, mRS score of 3 to 6 if the baseline NIHSS score was 8 to 14 points, and mRS score of 4 to 6 if the baseline NIHSS score was ≥ 15 points. The analysis revealed that patients with poor outcome had a wider range of BP variability than those with good outcome.

A post-hoc analysis of data from ECASS-I study was performed by Yong et al [51]. The correlation between BPV and good functional recovery (mRS score of 0 or 1) at day 90 in ischemic stroke patients was assessed. BPV was defined as SV. Decreased diastolic SV between 0 and 72 hours predicted favourable outcome. Besides, similar relationship was observed for systolic SV, but only in patients treated with rt-PA.

Fukuda et al assessed the relationship between the in-hospital day-by-day blood pressure variability during the acute and subacute stage of ischemic stroke and poor functional outcome at 3 months [52]. They included 2566 patients with acute ischemic stroke and measured BP daily as well as its variability (defined as SD, CV, and VIM). Then the authors evaluated 3-month functional outcome based on mRS. They showed that higher BPV during the subacute stage (but not during the acute) was associated with worse long-term functional outcome after ischemic stroke, independently of age, sex, body mass index, hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, estimated glomerular filtration rate, ischemic stroke subtype (cardioembolic or non-cardioembolic), infarct area (anterior or posterior circulation), antihypertensive agents administered during days 1-3, the baseline NIHSS score, thrombolytic therapy, and mean BP. Higher SD, CV, and VIM of SBP were also associated with neurological deterioration (defined as an increase in the NIHSS ≥ 2 during hospitalization) after adjustment for confounding factors.

Tziomalos et al assessed the relationship between BPV in the acute phase of ischemic stroke and the in-hospital outcome [53]. They evaluated SD and CV of
SBP and DBP in 608 patients during the first 2 days and the first 3 days after admission to the hospital. The outcome was in-hospital mortality and dependency rate (mRS score between 2 and 5). The authors found no association between BPV and the short-term outcome.

The relationship between BPV measured within 0-72 and 0-120 hours after admission and mRS was analyzed in the aforementioned study by de Havenon et al [42]. It was shown that higher SD, CV, and SV for SBP were predictors of poorer neurological outcome, while BPV for DBP was not significant.

In a prospective study by Wang et al, 873 patients with ischemic stroke were included in the analysis [54]. CV of SBP and CV of DBP calculated for the first 7 days of hospitalization were correlated with good neurological recovery (decrease in NIHSS score by ≥ 4 points from baseline or 0 point in NIHSS score), neurological deterioration (increase in NIHSS score by ≥ 1 point), poor functional outcome (2-5 points in mRS score) at 3 months as well as the risk of recurrent stroke, all-cause and cardiovascular mortality, and composite cardiovascular events (cardiovascular mortality, nonfatal stroke, and nonfatal myocardial infarction) within 12 months. They found that increased SBP-CV was significantly associated with less frequent good neurological recovery, neurological deterioration, poor functional outcome, higher risk of recurrent stroke and composite cardiovascular events. The same correlation was found for DBP-CV, except for association with poor functional outcome at 3 months (no correlation).

In another study, de Havenon et al. examined the relationship between SD, CV, and SV of SBP measured within 120 hours after admission in 110 patients with acute anterior circulation ischemic stroke with mRS score between 30 and 365 days [55]. Higher BPV was found to be associated with worse outcome, especially in patients with larger ischemic core volumes (defined as relative cerebral blood flow < 40% and absolute arterial tissue delay > 2 s) and larger hypoperfused volumes (defined as relative mean transit time > 135%).

**Long-term blood pressure variability**

In a 2014 study, the significance of long-term BPV in patients with ischemic stroke of all subtypes without atrial fibrillation was analyzed [56]. 632 ischemic stroke patients recruited within 14 days of presentation were included in the analysis. The patients were followed up (including BP measurement) every 3-4 months in an outpatient clinic (mean follow-up period was 76 ± 18 months). High BPV was defined as the fourth quartile of the study population. Outcome included all-cause and cardiovascular mortality, non-fatal recurrent stroke and nonfatal acute coronary syndrome. The analysis showed that higher SBP-CV was associated with higher incidence of all-cause and cardiovascular mortality. Furthermore, increased DBP-CV predicted the risk of cardiovascular mortality.

In another study, Lau et al assessed the relationship between visit-to-visit BPV and cardiovascular as well as all-cause mortality in patients with lacunar infarction [57]. 281 patients with lacunar infarction recruited within 14 days of presentation were followed up for 78 ± 18 months, on average. During each outpatient clinic visit made every 3-4 months, BP was measured and then systolic and diastolic BPV indices (defined as SD and CV) were calculated. Clinical outcome included all-cause and cardiovascular mortality, recurrent stroke and acute coronary syndrome. The relationship between BPV and clinical characteristics was assessed. Patients with a systolic (but not diastolic) BPV of the third tertile were associated with higher risk of all-cause and cardiovascular mortality. The relationship remained significant after adjustment for age, sex, mean systolic and diastolic BP, cardiovascular risk factors and cardiovascular-related comorbidities.

**Meta-analyses**

To our knowledge, only one meta-analysis for the influence of BPV in acute stroke on functional outcome exists was carried out to date [58]. Due to the heterogeneity of observational studies, the analysis included only 7 reports with one study on primary intracerebral haemorrhage [23, 34, 37-39, 50, 59]. It is noteworthy that only variability of BP within the first 7 days following acute stroke was assessed. It was suggested that higher BPV in patients with ischemic stroke is associated with worse functional outcome.

**Summary**

BPV was found to be a strong risk factor for stroke and other vascular events in high-risk patients, however little is known about the role of BPV after ischemic stroke [29]. Although some initial reports suggest their potential value in stroke prognosis, to date, few data on this issue are available and the existing results are inconsistent. Generally, the parameter which is most frequently reported as associated with prognosis after ischemic stroke is variability of SBP. In summary, it was shown that its higher values predict death, poor late outcome, haemorrhagic transformation, lesion growth assessed on MRI in case of occluded middle cerebral artery, neurologic deterioration or recurrent stroke [13, 23, 35-36, 38, 41-42, 44-48, 50-52, 54-55, 56].
studies is higher than in prospective studies [34-35, 38-39, 45, 52-54, 56-57].

As far as ischemic stroke subtype is concerned, in majority of the studies, this factor was not included in the analysis [10, 20, 31-32,34-37, 39, 43, 46, 48-49]. In several studies, BPV was found to be associated with the outcome after adjustment for, among others, stroke subtype [46-47, 50]. In one study, BPV was not associated with 3-month outcome independently of stroke subtype [38]. In few studies, only one stroke type was assessed: caused by middle cerebral artery occlusion [35] or internal carotid artery occlusion [45], lacunar [57], or anterior circulation ischemic stroke [55]. In one study, all types of stroke in patients without atrial fibrillation were included [56]. In one study, BPV was associated with long-term functional outcome independently of, inter alia, stroke subtype (cardioembolic vs. non-cardioembolic) or infarct area (anterior vs. posterior) [52]. In one study, it was shown that BPV did differ between stroke subtypes (anterior circulation, posterior circulation, or lacunar) and therefore they were not included in further analysis [34].

As demonstrated, studies of the relationship between BPV and outcome in ischemic stroke patients are very heterogeneous; however, the role of BPV seems to be important. Although no clinical trials assessing the effectiveness of BPV reduction in ischemic stroke were carried out to date, it is essential to identify subgroups of patients in whom its influence is highest and who might benefit from such therapies.


